A Patient with Glanzmann Thrombasthenia and Epistaxis Successfully Treated with Recombinant Factor Vila

Please copy the URL and add it into your RSS Feed Reader.

Facebook X Linkedin Weibo

Download PDF

Thromb Haemost 1996; 75(06): 982
DOI: 10.1055/s-0038-1650412

Original Article

Schattauer GmbH Stuttgart

Lilian Tengborn

¹The Coagulation Centre, Department of Internal Medicine, Sweden

,

Bjorn Petrusson

²ENT-Department, Sahlgrenska University Hospital, Goteborg, Sweden

Further Information

Received: 06 February 1996

Accepted after revision14 March 1996

Publication Date:
11 July 2018 (online)

References
1 Petruson B. Epistaxis, a clinical study with special reference to fibrinolysis. Acta Otolaryngol 1974; (Suppl. 314) Suppl 34-36

PubMed Google Scholar
2 Rodgers RCP, Levin J. A critical reappraisal of the bleeding time. Seminars in Thromb Haemost 1990; 16: 1-20

Article in Thieme Connect PubMed Google Scholar
3 Mannucci P, Vicente V, Vianello L, Cattaneo M, Alberca I. et al Controlled trial of desmopressin in liver cirrhosis and other conditions associated with a prolonged bleeding time. Blood 1986; 67: 1148-1153

PubMed Google Scholar
4 Hedner U. Experiences with recombinant factor Vila in haemophiliacs. In: Biotechnology of plasma proteins Albertini A, Lenfant CL, Mannucci PM, Sixma JJ. (eds) Curr Stud Hematol Blood Transf. Basel: Karger; 1991: 63-68
5 Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J. et al Clinical experience with recombinant factor Vila in patients with thrombocytopenia. Haemostasis 1996; (Suppl. 01) 26 Suppl 159-165

PubMed Google Scholar
6 Ciavarella N, Schiavoni M, Valenzano E, Mangini F, Inchingolo F. Use of recombinant factor Vila (NovoSeven) in the treatment of two patients affected by type III von Willebrand’s disease with inhibitor undergoing oral surgery. Haemost 1996; 26 Suppl (Suppl. 01) 150-155

PubMed Google Scholar